World News: 09:46 GMT Friday 10th August 2018. [Research and Markets via Globe Newswire via SPi World News]
Dublin, Aug. 10, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering. The global human microbiome market is nearly expected to grow by $521.23 million in 2022.This report provides an in-depth diverse perspective and the importance of human microbiome in health and disease-related conditions. Alterations in human microbiome occur by exposure to various extrinsic factors like diet, xenobiotics, drugs as well as pathogens which contribute to the pathogenesis of various metabolic, neurological, immunological, and cancer-promoting diseases. It will also disclose the key aspects of the human microbiome as well as the current biotechnological tools and techniques for studying the human microbiome.Various human microbial studies are known to identify and categorize the bacterial taxa and functions that are shared by a majority of individuals. This report will cover the factors which can affect the human microbiome as well as various studies which are well known and can be used as a tool for identifying the potential of the functional microbiome. It will also emphasize on the various microbiome-based markers which can be useful in determining the disease or the risk of disease and various approaches like Fecal Microbiota Transplant (FMT), Genetically engineered probiotics, etc. which have a profound effect in improving the microbiome condition.This report covers its market trends analysis and its growth in the commercial market. It will also include the major key players like Agilent technologies, Abbott, Biocartis, etc. which are actively working in this field and will also be discussed its future market scenario.This report will also focus on global market competitive analysis as well as the Major competitors/players in this market which are actively working on the human microbiome. It will also discuss the agreements, partnerships, collaborations/ Joint Ventures, acquisitions/mergers, new products launch, other key strategies in this field. 1 Table of Contents2 Executive Summary3 Introduction4 Human Microbiome: Overview4.1 Primitive Companion4.1.1 Microbiome Diversity4.1.2 Microbiome Commensal or Symbiosis4.1.3 Microbiome as a Human Organ4.2. The Common Core Microbiome in Human Large Intestine4.2.1 Phylogenetic Core4.2.2 Minimal Intestinal Metagenome4.3 Host Biology and Dysbiosis4.4 The Role of The Microbiome in Human Health and Disease4.4.1 The Microbiome and Human Health4.4.2 The Pediatric Microbiome4.4.3 Innate Immune Response4.4.4 Role of Microbiome in Diseases4.5 Microbiome as a Multipurpose Biomarker4.6 Microbiome Cross-Talk4.6.1 Microbiome-Microbiome Cross Talk4.6.2 Host-Microbiome Cross Talk4.7 The Human Microbiome Projects4.8 Current Methods for Studying the Human Microbiome4.9 Microbiome: Timeline4.10 Latest Research and Reviews5 Research Scope6 Research Methodology7 Research Approach8 Research Sources9 Technical Analysis9.1 Human Microbiome in IVD And Other Healthcare Applications9.1.1 Microbiome - Bacteria in Disease Processes9.1.2 Growing Interest in the Microbiome9.1.3 Metagenomics9.1.4 Metabolomic Profiling9.1.5 Microbiome Diagnostics9.1.6 Selected Molecular Microbiome-Based Tests9.1.7 Diagnostic Biomarkers9.1.8 Precision or Personalized Medicine Approaches9.1.9 Fecal Microbiome Transplantation (FMT)9.1.10 Other Selected Microbiome-Related Therapeutic Approaches9.1.11 Microbiome Modulators9.2 Human Microbiome in Disease9.2.1 Human Microbiome and Infectious Diseases22.214.171.124 Clostridium Difficile Infection126.96.36.199 Helicobacter Pylori Infection188.8.131.52 Bacterial Vaginosis184.108.40.206 HIV Infection220.127.116.11 Fungal Infection9.2.2 Human Microbiome and Liver Diseases9.2.3 Human Microbiota Associated with Gastrointestinal Malignancy18.104.22.168 Gastric Cancer22.214.171.124 Colorectal Cancer126.96.36.199 Esophageal Cancer9.2.4 Human Microbiome and Metabolic Disorders188.8.131.52 Obesity184.108.40.206 Type 2 Diabetes9.2.5 Human Microbiome and Autoimmune Disorder220.127.116.11 Celiac Disease18.104.22.168 Rheumatoid Arthritis22.214.171.124 Ankylosing Spondylitis126.96.36.199 Psoriatic Arthritis188.8.131.52 Systemic Lupus Erythematosus184.108.40.206 Sjogren's Syndrome220.127.116.11 Vasculitis9.2.6 Human Microbiome and Other Diseases18.104.22.168 Allergic Diseases22.214.171.124 Psychiatric Diseases126.96.36.199 Atherosclerosis188.8.131.52 Paneth Cell Dysfunction184.108.40.206 Cerebrovascular Disease220.127.116.11 Multiple Sclerosis9.3 Advancements in Human Microbiome Technology9.4 Ingredients Effecting Human Microbiome9.4.1 Proteins9.4.2 Lipids9.4.3 Carbohydrates9.4.4 Glutens9.4.5 Polyphenols9.4.6 Green Vegetables9.4.7 Fruits9.4.8 Dairy products9.4.9 Meat9.4.10 Junk Foods9.4.11 Fermented Foods9.4.12 Processed Foods9.4.13 Antibiotics9.4.14 Probiotics9.4.15 Prebiotics9.4.16 Other Active agents10 Mode of Administration of Microbiome Products11 Microbiome Product forms 12 Market Analysis 12.1 Market Overview 12.2 Human Microbiome Market Segmentation 12.2.1 Based on Application18.104.22.168 Therapeutic 22.214.171.124 Diagnostic 12.2.2 Based on Disease Type12.2.3 Based on Product Type 126.96.36.199 Prebiotics 188.8.131.52 Foods 184.108.40.206 Drugs 220.127.116.11 Diagnostic Devices 18.104.22.168 Nutritionally Incomplete Formulae 22.214.171.124 Formulae for Metabolic Disorders126.96.36.199 Nutritionally Complete Formulae 188.8.131.52 Oral Rehydration Products 184.108.40.206 Other Probiotics Supplements 12.2.4 Based on Distribution Channel 12.2.5 Based on End Users 12.2.6 Based on Geography 12.3 Global Human Microbiome Market Competitive Analysis 12.4 Human Microbiome Market Major Market Competitors/Players 13 Market Trend Analysis 13.1 Drivers 13.2 Restraints13.3 Opportunities 13.4 Threats 13.5 Application Analysis 13.6 Product Analysis 13.7 Research Scenario 13.8 Emerging Markets 13.9 Supply Chain Analysis 13.10 Futuristic Market Scenario13.11 Burning Issues 14 Key Microbiome Players (Company Profiling) 14.1 4D Pharma plc 14.2 Abbott Diagnostics14.3 Agilent Technologies Inc.14.4 Anaeropharma Science 14.5 AOBiome, LLC 14.6 Aperiomics, Inc.14.7 Atlas Biomed 14.8 AvidBiotics 14.9 Beckman Coulter/Danaher14.10 Becton, Dickinson and Company (BD) 14.11 Biocartis Group14.12 C3J Therapeutics (formerly C3 Jian) 14.13 Crestovo (Finch Therapeutics Group)14.14 Danaher Corporation 14.15 Eppendorf AG 14.16 Evelo Biosciences 14.17 Evolve Biosystems 14.18 Finch Therapeutics Group 14.19 One Codex 14.20 OpenBiome 14.21 Optibiotix 14.22 OraSure Technologies, Inc. 14.23 Osel, Inc. 14.24 PerkinElmer, Inc. (Pe) 14.25 Pfizer, Inc.14.26 Phase Genomics 14.27 Proderm IQ 14.28 Prodigest 14.29 Promega Corporation 14.30 PureFlora Inc. 14.31 QIAGEN 14.32 Quay Pharma 14.33 Whole Biome 14.34 Xycrobe Therapeutics, Inc. 14.35 Zymo Research15 Key Microbiome Developments 15.1 Agreements, Partnerships, Collaborations and Joint Ventures 15.2 Acquisitions & Mergers15.3 New Product Launch 15.4 Expansions 15.5 Other Key Strategies For more information about this report visit
Did you know that we also offer Custom Research? Visit our page to learn more and schedule a meeting with our Custom Research Manager.
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals
Globe Newswire: 09:46 GMT Friday 10th August 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.